AdvertisementSupported byBy Chad BrayLONDON — Fresenius, one of Europe’s largest health care providers, said on Tuesday that it had agreed to acquire IDC Salud Holding, Spain’s largest private hospital operator.The deal would expand the operations of Fresenius’s Helios unit, which is already Germany’s largest hospital operator, by adding IDC Salud Holding, known as Quirónsalud, for 5.8 billion euros, or about $6.5 billion. It is the first acquisition outside Germany by the Fresenius Helios unit.“This acquisition combines two leaders in terms of quality and size,” Stephan Sturm, the Fresenius chief executive, said in a news release. “For Fresenius, this acquisition is another strategic step towards offering quality and yet affordable care for patients worldwide.”Based in Bad Homburg, Germany, Fresenius operates four main health care businesses, including Fresenius Medical Care, one of the world’s largest providers of treatments for people with chronic kidney failure. The company has more than 200,000 employees and had sales of €27.6 billion in 2015.Under the terms of the agreement, Fresenius would acquire 100 percent of the Spanish hospital operator from the private equity firm CVC Capital Partners and would keep the Quirónsalud chief executive, Víctor Madera, and other members of Quirónsalud’s management board. CVC first acquired a stake in the business, then known as Capio Spain, in March 2011 from the Swedish health care group Capio.The transaction is subject to regulatory approval and is expected to close in the fourth quarter of this year or the first quarter of 2017.Quirónsalud was created two years ago by the merger of IDC Salud and Grupo Hospitalario Quirón.It operates a network of 43 hospitals, 39 outpatient centers and 300 occupational risk prevention centers in Spain, and it employs about 35,000 people. The company expects €2.5 billion in sales in 2016.Fresenius said the companies would continue to operate under the Helios brand in Germany and the Quirónsalud brand in Spain after the transaction is completed. It also said it expected €50 million in annual, pretax cost savings after the deal.Mr. Madera would continue to serve as the chief executive of the Quirónsalud business.Fresenius said it would issue 6.1 million shares, valued at about €400 million, to Mr. Madera as part of the transaction. The shares would be subject to a two-year lockup period.Follow Chad Bray on Twitter @Chadbray.Advertisement